Novo Nordisk (NOVO) Status update summary

Strategic Focus and Pipeline Overview

• Emphasis on innovation and addressing unmet needs in diabetes and obesity, with a broad R&D pipeline targeting glycemic control, comorbidities, and differentiated obesity treatments.

• Recent organizational changes include a dedicated product and portfolio strategy unit to streamline pipeline input and commercialization.

• Strategic aspirations include raising the innovation bar, expanding into cardiovascular and emerging therapy areas, and achieving over DKK 25 billion in obesity care sales by 2025.

• The pipeline features leading assets in the incretin space and beyond, sourcing both internal and external innovation, with multiple late-stage and early assets in development.

• ESG priorities include progress towards zero environmental impact and being recognized as a sustainable employer.

Diabetes Portfolio and Clinical Outcomes

• Semaglutide demonstrates superior cardiovascular and renal outcomes, with a 26% MACE risk reduction in type 2 diabetes and significant benefits in kidney disease and PAD as shown in FLOW, SOUL, and STRIDE trials.

• Semaglutide addresses four of five ADA 2025 treatment goals for T2D, with label expansions for Ozempic and Rybelsus underway.

• Comprehensive clinical data show semaglutide's efficacy in glycemic control, weight loss, MACE, kidney outcomes, and mortality reduction.

• GLP-1 diabetes market penetration remains low globally at 7%, but the company holds a 60% volume market share; oral semaglutide (Rybelsus) is the first and only oral GLP-1.

• Diabetes prevalence is rising, with 850 million adults projected to have diabetes by 2050 and significant comorbidities.

Obesity Portfolio and Market Expansion

• Less than 5% of patients with obesity are currently treated, highlighting significant growth potential; over 1.7 billion people globally are overweight or obese.

• Wegovy remains the only obesity drug with proven cardiovascular benefits, and the pipeline includes Cagrilintide, CagriSema, amycretin, triagonists, and small molecules.

• Real-world evidence confirms robust weight loss and cardiovascular risk reduction with semaglutide and Wegovy, outperforming RCTs in some measures; SELECT and SHAPE studies support cardiovascular benefits.

• Semaglutide 2.4 mg shows benefits in MASH and heart failure, with regulatory decisions expected in H2 2025.

• Focus on developing differentiated obesity treatments addressing weight loss magnitude, comorbidities, and patient preferences.